文章摘要
江旭,刘尚全,王继政.钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并心血管疾病的临床进展[J].中国医药导刊,2019,21(6):352-355.
钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并心血管疾病的临床进展
Clinical Advances in the Treatment of Type 2 Diabetes Mellitus with Cardiovascular Disease by Sodium-glucose Cotransporter 2 Inhibitors
投稿时间:2019-05-16  修订日期:2019-06-07
DOI:
中文关键词: 2型糖尿病  心血管疾病  钠-葡萄糖协同转运蛋白2抑制剂  安全性  有效性
英文关键词: Type 2 diabetes mellitus  Cardiovascular disease  Sodium-glucose cotransporter 2 inhibitors  Safety  Effectiveness
基金项目:
作者单位E-mail
江旭 安徽医科大学 1974094612@qq.com 
刘尚全 安徽医科大学第三附属医院  
王继政 安徽医科大学第三附属医院  
摘要点击次数: 55
全文下载次数: 87
中文摘要:
      2型糖尿病(T2DM)及心血管疾病是常见的慢性进展性疾病,具有较高的发病率及死亡率,两者常互为合并症,互相影响病程的进展。随着2型糖尿病进展,胰岛功能下降,传统降糖药物很难从根本上控制血糖,并出现体重增加或低血糖等不良作用,而心血管疾病的伴发更增加了治疗的难度。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂作为一种可以解决以上问题的新型降糖药物,有效、安全、便捷,多方面发挥降糖作用,低血糖的发生风险极小,也可发挥减重、调脂、降压等作用,保护心功能,甚至可降低心血管死亡风险,故SGLT2抑制剂在糖尿病合并心血管疾病的治疗领域存在广阔的应用空间。但是,其在糖尿病合并心血管疾病方面的安全性仍需谨慎。
英文摘要:
      Type 2 diabetes mellitus (T2DM) and cardiovascular diseases are common chronic progressive diseases with high morbidity and mortality. They are often connected with each other and affect the progress of disease course. With the course of disease, and the reduction of pancreatic islet function, it is difficult for traditional hypoglycemic agents to control blood glucose radically, and it appears some adverse effects such as gaining weight or hypoglycemia, while the accompany of cardiovascular diseases increase the difficulty of the treatment of T2DM. As a new type of oral glucose-lowering drugs, sodium-glucose cotransporter 2 (SGLT2) inhibitor solves the problem above effectively, safely and conveniently, it also reduces the risk of hypoglycaemia, it plays a role of reducing weight, regulating blood lipid, lowering blood pressure, protecting heart function, and even reducing the risk of cardiovascular death, so the SGLT2 inhibitors have broad application in the field of diabetic cardiovascular disease. However, the safety of the drug in patients who have diabetes mellitus with cardiovascular disease needs cautious.
查看全文   查看/发表评论  下载PDF阅读器